U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07459114) titled 'TGD001 Treatment in Thrombotic Microangiopathies' on Feb. 21.
Brief Summary: This is a Phase 1/2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or clinical diagnosis of an acute Thrombotic Microangiopathy (TMA) episode. The trial is an open-label, dose escalation and expansion basket trial.
Study Start Date: May 31
Study Type: INTERVENTIONAL
Condition:
Thrombotic Microangiopathies
ITP Immune-Mediated Thrombocytopenia
Intervention:
DRUG: TGD001
IV bolus administration
Recruit...